Key result
Treatment-naïve individuals living with HIV exhibited significantly greater arterial stiffness, measured by a 0.5 m/s higher carotid-femoral pulse wave velocity, compared to uninfected controls.
Why the study?
HIV infection increases cardiovascular disease risk, endothelial dysfunction, and arterial stiffness, but aortic stiffness and central hemodynamics had not been assessed in young individuals with recent diagnosis without antiretroviral therapy.
Does treatment-naïve HIV infection increase aortic stiffness and alter central hemodynamics compared to healthy controls?
Cross-Sectional (n=102)
No
Does treatment-naïve HIV infection increase aortic stiffness and alter central hemodynamics compared to healthy controls?
Effect estimate: Mean difference 0.5 m/s (95% CI 0.26 to 0.86)
Absolute Event Rate: 7.3% vs 6.7%
p-value: p=< 0.01
Treatment-naïve HIV infection is associated with increased aortic stiffness and altered central hemodynamics, highlighting early subclinical cardiovascular risk in this population.
May signal early subclinical CV risk in untreated HIV; hypothesis-generating for ART effects on stiffness.
Background Human immunodeficiency virus (HIV) infection is associated with a greater risk of cardiovascular disease (CVD). HIV infection causes a chronic inflammatory state and increases oxidative stress which can cause endothelial dysfunction and arterial stiffness. Aortic stiffness measured by carotid femoral-pulse wave velocity (cfPWV) and central hemodynamics are independent cardiovascular risk factors and have the prognostic ability for CVD. We assessed cfPWV and central hemodynamics in young individuals with recent HIV infection diagnosis and without antiretroviral therapy. We hypothesized that individuals living with HIV would present greater cfPWV and central hemodynamics (central systolic blood pressure and pulse pressure) compared to uninfected controls. Methods We recruited 51 treatment- naïve individuals living with HIV (HIV(+)) without previous CVD and 51 age- and sex-matched controls (HIV negative (−)). We evaluated traditional CVD risk factors including metabolic profile, blood pressure (BP), smoking, HIV viral load, and CD4 + T-cells count. Arterial stiffness and central hemodynamics were evaluated by cfPWV, central systolic BP, and central pulse pressure (cPP) via applanation tonometry. Results HIV(+) individuals presented a greater prevalence of smoking, reduced high-density lipoprotein cholesterol, and body mass index. 65.9% of HIV(+) individuals exhibited lymphocyte CD4 + T-cells count < 500 cells/μL. There was no difference in brachial or central BP between groups; however, HIV(+) individuals showed significantly lower cPP. We observed a greater cfPWV (mean difference = 0.5 m/s; p < 0.01) in HIV(+) compared to controls, even after adjusting for heart rate, mean arterial pressure and smoking. Conclusion In the early stages of infection, non-treated HIV individuals present a greater prevalence of traditional CVD risk factors, arterial stiffness, and normal or in some cases central hemodynamics.
No takes yet. Share an insight, caveat, or question.
Martínez-Ayala et al. (2020) conducted a cross-sectional in Treatment-naïve HIV infection (n=102). HIV infection (treatment-naïve) vs. Healthy controls (HIV negative) was evaluated on Carotid-femoral pulse wave velocity (cfPWV) (Mean difference 0.5 m/s, 95% CI 0.26 to 0.86, p=< 0.01). Treatment-naïve individuals living with HIV exhibited significantly greater arterial stiffness, measured by a 0.5 m/s higher carotid-femoral pulse wave velocity, compared to uninfected controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: